Blog

Cesar Perez: During the ASCO 2024 Educational Session, we will discuss the plethora of novel agents for Head and Neck Cancer

Photo from Cesar Perez/LinkedIn

May 16, 2024, 14:31

Cesar Perez: During the ASCO 2024 Educational Session, we will discuss the plethora of novel agents for Head and Neck Cancer

Cesar Perez, Director of Drug Development at Lake Nona DDU of Florida Cancer Specialists and Research Institute, shared on LinkedIn:

“Drug Development for patients with Head and Neck Cancer has lagged behind over the last decade.

However, a new era is approaching.

During the ASCO 2024 Educational Session, we will discuss the plethora of novel agents in development for the disease, which will bring hope for a population in so much need for new options.

‘Breaking Ground in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Novel Therapies Beyond PD-L1 Immunotherapy’.”

Source: Cesar Perez/LinkedIn

ASCO ASCO 2024 ASCO 2024 Educational Session ASCO Annual Meeting cancer Cesar Perez Florida Cancer Specialists and Research Institute Head and Neck Cancer head and neck squamous cell carcinoma Lake Nona DDU OncoDaily Oncology PD-L1 immunotherapy

Mark Ruffalo and Brain Cancer: How He Went Against, How He Survived, and More

Sharon Osbourne and Colon Cancer: How She Went Against, How She Survived, and More

Marcia Cross and Anal Cancer: How She Went Against, How She Survived, and More

Pancreatic Cancer: Symptoms, Causes, Types, Diagnosis & Treatment

FDA approves Methotrexate for Pediatric acute Lymphoblastic Leukemia

Special Coverage